Pharma The rise of GLP-1 receptor agonists, oral obesity drugs, and advanced diabetes treatments is redefining the U.S
Although each of these peptides differ from each other, similarities also exist
Effects of sustained treatment with lixisenatide on gastric emptying and postprandial glucose metabolism in type 2 diabetes: A randomized controlled trial
Both the semaglutide and tirzepatide shortages that made compounding legally available were declared resolved in 2024 and 2025, the compounding wind-down deadlines have passed, and in April 2026 the FDA proposed closing the remaining legal pathway entirely
How Long Should You Use It
About one in eight US adults is taking a GLP-1 medication, the class that includes Ozempic, Wegovy, Mounjaro, and Zepbound, double the share of eighteen months before